Recent insight into BACE1 as a potential target for treatment of Alzheimer's disease
Atta, A., darwish, K., Elgawish, M., Moustafa, S., Helal, M. (2021). Recent insight into BACE1 as a potential target for treatment of Alzheimer's disease. EKB Journal Management System, 5(Chemistry), 100-111. doi: 10.21608/rpbs.2021.55758.1087
Asmaa Mohamed Atta; khaled Mohamed darwish; Mohamed Saleh Elgawish; Samia Mahmoud Moustafa; Mohamed aboelhassan Helal. "Recent insight into BACE1 as a potential target for treatment of Alzheimer's disease". EKB Journal Management System, 5, Chemistry, 2021, 100-111. doi: 10.21608/rpbs.2021.55758.1087
Atta, A., darwish, K., Elgawish, M., Moustafa, S., Helal, M. (2021). 'Recent insight into BACE1 as a potential target for treatment of Alzheimer's disease', EKB Journal Management System, 5(Chemistry), pp. 100-111. doi: 10.21608/rpbs.2021.55758.1087
Atta, A., darwish, K., Elgawish, M., Moustafa, S., Helal, M. Recent insight into BACE1 as a potential target for treatment of Alzheimer's disease. EKB Journal Management System, 2021; 5(Chemistry): 100-111. doi: 10.21608/rpbs.2021.55758.1087

Recent insight into BACE1 as a potential target for treatment of Alzheimer's disease

Records of Pharmaceutical and Biomedical Sciences
Article 15, Volume 5, Chemistry - Serial Number 1, January 2021, Page 100-111  XML PDF (743.54 K)
Document Type: Original Article
DOI: 10.21608/rpbs.2021.55758.1087
View on SCiNiTO View on SCiNiTO
Authors
Asmaa Mohamed Atta email 1; khaled Mohamed darwish2; Mohamed Saleh Elgawishorcid 3; Samia Mahmoud Moustafa4; Mohamed aboelhassan Helal5
1Pharmaceutical Chemistry Department, Faculty of Pharmacy, Badr University
2Medicinal Chemistry Department, Faculty of Pharmacy, Suez Canal Uniersity
3Medicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University
4Medicinal Chemistry department , Faculty of Pharmacy,Suez Canal University
5Medicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University Biomedical Sciences Program, University of Science and Technology, Zewail City of Science and Technology, Giza, Egypt
Abstract
Alzheimer’s disease (AD) is one of the most common progressive neurodegenerative diseases that represents about 60-80 % of total cases of dementia all over the world. Beta secretase (BACE1) is a membrane-anchored aspartic protease which cleaves the peptide bond between Met671-Asp672 of APP (amyloid precursor protein) where its activity is the rate limiting step of producing amyloid β, the primary neuropathological hallmark of Alzheimer's disease (AD). Therefore, inhibitors of this enzyme have the potential to be a promising and attractive target for intervention of potent therapeutics for treatment AD. Actually, there are many challenges facing the development of effective drug-like BACE1 inhibitors including penetration of BBB and selectivity against other proteases. However, many efforts have been devoted by pharmaceutical industries and academia for development of small size, potent, selective and biologically active BACE1 inhibitors. Till now, none of which is FDA approved but some of which have exhibited clinical potential. In this article, we outlined overview of beta secretase inhibitors that have been designed and developed for treatment of AD.
Keywords
Alzheimer's disease; AD; BACE1; BACE1 inhibitors
Statistics
Article View: 407
PDF Download: 445